Inhalation of Low Molecular Weight Heparins as a prophylaxis to prevent SARS-CoV-2 infection

Project description Existing drug prevents SARS-CoV-2 infection There is a very urgent need for SARS-CoV-2 preventive drugs to stop the COVID-19 pandemic. We have found that infection of cells with SARS-CoV-2 is blocked by the anti-clotting drug low molecular weight heparin. This drug blocks the binding of the virus to the cells, which greatly reduces or even prevents infection.In this project we will investigate whether inhalation of low molecular weight heparin can be used as a preventive drug against SARS-CoV-2. To this end, we have developed animal-free innovations to determine the effectiveness of the intervention and to unravel the mechanism of action of this drug.